Literature DB >> 21214677

Triple-negative breast cancer: histological subtypes and immunohistochemical and clinicopathological features.

Yuko Ishikawa1, Jun Horiguchi, Hiroyuki Toya, Hiroki Nakajima, Mitsuhiro Hayashi, Nobumi Tagaya, Izumi Takeyoshi, Tetsunari Oyama.   

Abstract

To reveal heterogeneous properties of triple-negative (TN) breast cancers (estrogen receptor negative, progesterone receptor negative and HER2 negative) and to clarify whether the developmental pathways to TN breast cancer are single or multiple, we conducted clinicopathological and immunohistochemical studies on TN breast cancers, with special reference to comparison of the invasive component (iIC) and the ductal component (dcIC) of invasive TN breast cancer and pure TN ductal carcinoma in situ (TNDCIS). Tumor tissues were obtained from 97 patients with TN invasive carcinoma and 10 patients with TNDCIS. Two histological subclassifications, "atypical" medullary carcinoma (type A, n=16) and carcinoma with a central acellular zone (type B, n=11), were distinguished from conventional ductal carcinoma. Other invasive ductal carcinomas were classified as type C (n=64) and special types were classified as type D (n=5). The follow-up period for the 96 patients ranged from 5 to 147.8 months (mean, 47.6 months). Out of 97 cases, dcIC was present in 29 (30%) cases and type A and B had significantly few ductal components, 0% and 18%, respectively. There were only six (6%) cases with non-TN cells in dcIC and TN cells in iIC and five of them were type C. In 13 (13%) cases, epidermal growth factor receptor (EGFR) expression existed only in iIC. Therefore, most of the TN carcinoma develops originally and rapidly invades at the early stage, especially in types A and B. The relapse rate of type B was the highest (36.4%) and the overall survival of patients with type B was the shortest (P=0.02), which indicates that the prognosis of type B is significantly worse than the other types.
© 2011 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21214677     DOI: 10.1111/j.1349-7006.2011.01858.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  10 in total

1.  Clinicopathological Features of Triple Negative Breast Carcinoma.

Authors:  Gowry Maram Reddy; Pooja K Suresh; Radha R Pai
Journal:  J Clin Diagn Res       Date:  2017-01-01

2.  Clinicopathological Study of Triple Negative Breast Cancers.

Authors:  Gunadala Ishitha; Marie Therese Manipadam; Selvamani Backianathan; Raju Titus Chacko; Deepak Thomas Abraham; Paul Mazhuvanchary Jacob
Journal:  J Clin Diagn Res       Date:  2016-09-01

3.  An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy.

Authors:  Jing Zhang; Yahong Wang; Quangui Yin; Wei Zhang; Tongxian Zhang; Yun Niu
Journal:  Int J Clin Exp Pathol       Date:  2013-06-15

Review 4.  Duodenal Metastasis in Triple-Negative Invasive Ductal Breast Carcinoma With Negative Mammography: A Case Report and Review of the Literature.

Authors:  Naila A Khan; Sonha T Nguyen; Phildrich G Teh; Vishal N Ranpura; Taruna Bhatia
Journal:  Perm J       Date:  2021-07-28

5.  Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile.

Authors:  Satoshi Takahashi; Aye Aye Thike; Valerie Cui Yun Koh; Hironobu Sasano; Puay Hoon Tan
Journal:  Virchows Arch       Date:  2018-07-23       Impact factor: 4.064

6.  Clinicopathological features and prognosis of triple negative breast cancer in Kuwait: A comparative/perspective analysis.

Authors:  Mohammed S Fayaz; Mustafa S El-Sherify; Amany El-Basmy; Sadeq A Zlouf; Nashwa Nazmy; Thomas George; Susan Samir; Gerges Attia; Heba Eissa
Journal:  Rep Pract Oncol Radiother       Date:  2013-09-26

7.  ESM1 promotes triple-negative breast cancer cell proliferation through activating AKT/NF-κB/Cyclin D1 pathway.

Authors:  Wentong Liu; Yang Yang; Bincan He; Fengjun Ma; Fengzeng Sun; Min Guo; Min Zhang; Zhiqiang Dong
Journal:  Ann Transl Med       Date:  2021-04

Review 8.  Triple negative breast cancer: the kiss of death.

Authors:  Adriana-Andreea Jitariu; Anca Maria Cîmpean; Domenico Ribatti; Marius Raica
Journal:  Oncotarget       Date:  2017-07-11

Review 9.  The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer.

Authors:  Aurelio Bartolome Castrellon; Ihor Pidhorecky; Vicente Valero; Luis Estuardo Raez
Journal:  Oncol Rev       Date:  2017-03-17

10.  Defining the area of mitoses counting in invasive breast cancer using whole slide image.

Authors:  Asmaa Ibrahim; Ayat G Lashen; Ayaka Katayama; Raluca Mihai; Graham Ball; Michael S Toss; Emad A Rakha
Journal:  Mod Pathol       Date:  2021-12-11       Impact factor: 8.209

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.